ESG Report 2020

Rheumatoid Arthritis Drug Research and Development Achievements The Group's independently-developed new Compared with other non-selective drug for rheumatoid arthritis is a small- inhibitors available in the market, the molecule selective inhibitor of tyrosine Group's self-developed new drug for kinase, which can reduce the synthesis and rheumatoid arthritis is more effective and secretion of inflammatory mediators and has fewer adverse effects. During the Year, inhibit the occurrence of inflammation, t h e N a t i o n a l M e d i c a l P r o d u c t s thereby achieving relief and treatment of Administration issued the Group a clinical rheumatoid arthritis. The drug is intended trial notice, approving clinical trials on the for the treatment of moderate to severe new drug for rheumatoid arthritis. It is active rheumatoid arthritis. At present, there expected to provide a more effective and are no new drugs of similar selective safer treatment option for patients with inhibitors available in the Country. active rheumatoid arthritis. During the Year, the “ Tildipirosin Bulk residue and safety, Tildipirosin has a very Medicine ” and “ Tildipirosin Injection ” , which wide application in animal husbandry. were jointly declared by The United Animal With a professional research and Healthcare and other pharmaceutical development team, strong technical skills, companies, obtained the certificate in new abundant resource investment, continuous veterinary drug issued by the Ministry of innovation capabilities and scientific Agriculture and Rural Affairs of China, and enterprise management, The United Animal was approved for listing. Tildipirosin is an Healthcare has continued to develop and antibacterial agent used for the treatment innovate on the application of veterinary of respiratory diseases in swine and cattle pharmaceuticals, and has reached a high caused by Gram-positive and negative level in transforming science and bacteria. With the advantages of specific technological achievements. use among animals, low dosage, low Veterinary Medicine Research and Development Achievements As of 31 December 2020, the Group had a total of multiple injection generic drugs, with 17 26 generic drugs and new drug projects under consistency evaluation projects that were in research, including 10 chemical drugs and 16 progress. The Group currently has a variety of key biological products, 3 of which were pending research and development products. The product approval for production and 3 were in clinical treatment areas and the corresponding stages of stage, 1 was pending clinical approval, and 19 were research and development are as shown above in the preclinical stage. In addition, the Group (Key Products under Research). It is expected that actively responded to the national Quality and these products will lay a good foundation for the Efficacy Consistency Evaluation of Generic Drugs, Group's sustainable development in its future and carried out a consistency evaluation study for operations. 53 Environmental, Social and Governance Report 2020 The United Laboratories International Holdings Limited